Info

Editorial note: This article covers documented side effects of GLP-1 receptor agonists and Novi's published cancellation and refund policy. It is educational, not medical advice. Side effects vary among individuals, and any patient experiencing symptoms should communicate directly with their prescriber. Compounded medications are not FDA-approved finished drugs.

Two facts about a compounded GLP-1 telehealth subscription are worth knowing in the same breath. First: GLP-1 medications work in part because they cause gastrointestinal side effects — that's the mechanism, slowed gastric emptying and altered appetite signaling, doing its job. Second: once Novi dispenses a prescription, refunds aren't available, regardless of whether the patient tolerates the medication.

Those two facts intersect for prospective patients. The decision to start treatment is also a financial commitment to the 3-month subscription window, with limited exit pathways for tolerability reasons. This article covers what side effects to actually expect from the medications Novi prescribes, what Novi's clinical safety mechanics look like, and exactly what the cancellation and refund terms say.

The Side Effect Profile of GLP-1 Medications — What's Actually Documented

The published clinical trial data and post-marketing surveillance for semaglutide and tirzepatide describe a fairly consistent side effect profile across studied populations. The 2026 systematic review aggregating 22 randomized controlled trials across 41,757 individuals reported the following frequency ranges for GLP-1 receptor agonists versus placebo:

Nausea — 14% to 28% of trial participants on GLP-1 medications, versus 5% to 10% on placebo. This is the most commonly reported side effect across the class and tends to be most pronounced in the first weeks of treatment and during dose escalation.

Vomiting — 6% to 12% on GLP-1 medications versus 2% to 4% on placebo. Less common than nausea but a significant minority experience it, particularly at higher doses.

Diarrhea — 8% to 20% versus 4% to 7%. Highly variable across trials and individuals.

Constipation — Reported in clinical trials at meaningful frequency. Often results from slowed gastric and intestinal motility, which is part of the medication's mechanism.

Decreased appetite — This is, technically, the desired effect. It also represents a significant change from baseline that some patients find uncomfortable, particularly if it interferes with adequate hydration or nutrition.

For context: the trials of brand-name tirzepatide and brand-name semaglutide found that, despite these effects, the risk of pancreatitis and serious adverse events remained comparable to placebo. The class is not characterized by a high rate of severe events. It is characterized by a high rate of moderate gastrointestinal effects, particularly during titration.

One interesting comparative finding from preclinical research: dual GLP-1/GIP agonists like tirzepatide may be associated with somewhat fewer gastrointestinal adverse events than equipotent doses of pure GLP-1 agonists like semaglutide, with similar weight-loss effects. The clinical implication for individual patients is uncertain — both molecules have substantial side effect rates in real-world use.

Serious Risks and Contraindications

The contraindication list for GLP-1 receptor agonists includes specific conditions that any reputable prescribing process screens for.

Personal or family history of medullary thyroid carcinoma. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN2). Personal history of pancreatitis. Severe gastroparesis or other significant gastrointestinal disorders. Pregnancy or active attempts to conceive. Active gallbladder disease. Severe renal impairment.

Some of these are absolute contraindications (medullary thyroid carcinoma history, MEN2). Others are relative — risks to be weighed by a prescribing clinician against potential benefit.

Less common but documented serious risks include acute pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), acute kidney injury (often related to dehydration from severe nausea/vomiting), and rare reports of intestinal obstruction or ileus. The FDA's adverse event reporting system has captured these signals across both brand-name and compounded GLP-1 products.

The agency's reporting on compounded versions specifically, as of early 2025: more than 455 adverse event reports for compounded semaglutide and more than 320 for compounded tirzepatide. Many involved dosing errors from patients drawing incorrect amounts from multidose vials — a delivery format more common in compounded preparations than in brand-name pen injectors. Some required hospitalization. The dosing-error pattern factored into the FDA's regulatory posture leading to the April 30, 2026 503B exclusion proposal. We cover the regulatory mechanics in more depth in our Novi compounded vs brand analysis.

How Novi's Screening Process Works

Per Novi's published intake description, the medical questionnaire collects current weight and BMI, medical history, existing medications, prior weight-loss efforts, and lifestyle context. A US-licensed clinician reviews the submission. If the clinician determines additional information is needed, a virtual visit may be scheduled. If the clinician determines treatment is medically appropriate, a prescription is issued.

The platform's published clinical team — including Daniel Funsch, MD; Michael Wasef, MD; Takashi Nakamura, MD; and several nurse practitioners — reviews intakes and conducts virtual consultations. Novi states that providers retain the authority to deny treatment for any reason consistent with their clinical judgment, including potential misuse risk.

The honest read on telehealth eligibility screening generally — Novi included — is that it's only as thorough as the patient's disclosure. The intake questionnaire format is well-suited to identifying named contraindications when patients accurately report family history and existing conditions. It is less able to identify subclinical issues that might emerge in an in-person physical examination. Novi's published telehealth consent acknowledges this — explicitly noting that telehealth providers rely primarily on patient-reported data rather than in-person physical exams.

For patients with uncertain medical histories, complex medication regimens, or known cardiovascular or endocrine concerns, the right diligence is to discuss the prospective treatment with an existing primary care or specialty physician before completing a telehealth intake. The telehealth platform isn't designed to replace that consultation — it's designed to handle the prescribing pathway after eligibility is reasonably established.

What Side Effects Look Like in Practice — and What to Do About Them

Most patients on a GLP-1 medication experience some form of gastrointestinal effect during the first weeks. The standard clinical approach to minimize this is gradual dose titration — starting at the lowest effective dose, holding for several weeks, and stepping up only if tolerated. Novi's published process aligns with this approach.

Practical management strategies for common effects, all of which a patient should discuss with their prescriber rather than self-direct:

For nausea: smaller, more frequent meals; avoiding very fatty or rich foods, especially during titration; staying hydrated; eating slowly. If nausea is severe or persistent, the prescriber may delay a planned dose increase.

For constipation: adequate fluid intake, fiber-rich foods, gentle physical activity. The mechanism here is the same gastric-motility effect that causes the appetite suppression, so this is a frequent companion symptom. For comparison context on a non-pharmaceutical approach to GLP-1 mechanism that produces some similar side effects, see the analysis at our gelatin trick side effects coverage.

For dizziness or low blood sugar (more relevant for patients with diabetes or those taking other glucose-lowering medications): communicate immediately with the prescriber; avoid driving or operating machinery if symptoms are present.

For severe abdominal pain (especially radiating to the back, with vomiting): treat as a potential pancreatitis warning sign. Stop the medication and seek immediate medical evaluation. Do not wait for a telehealth appointment for severe abdominal symptoms.

The Cancellation and Refund Terms — In Detail

This is where Novi's published terms become specific in ways that matter for tolerability decisions.

The 3-month minimum commitment is contractual. Per the published Terms of Service: the first month plus the next two months are charged at time of purchase and are non-refundable, unless a provider determines that treatment is not medically appropriate before any prescription is dispensed. After that point, the published terms do not provide a refund mechanism.

To stop further charges after the 3-month commitment is completed, cancellation must be submitted at least 15 days before the next monthly processing date. Cancellation can be made by emailing support@joinnovi.com or through the patient dashboard.

Once a prescription is dispensed or shipped, that prescription cannot be returned or refunded under any condition listed in the published terms. The terms further state: “False credit card disputes will be aggressively defended and customers who attempt to dispute charges to circumvent the 3-month commitment will be sent to collections and/or have further legal action pursued.”

What this means in practice for a patient experiencing significant side effects in month one of a 3-month commitment:

Communicating with the prescriber to discuss dose adjustment, alternative medications, or temporary holds is the available pathway within the platform. Discontinuing the medication doesn't, by itself, end the financial commitment to the remaining months. Whether and how Novi's clinical team handles tolerability-based discontinuation requests in practice — including whether unused future months can be paused, refunded, or applied to a different course — is a question prospective patients should clarify with support@joinnovi.com before signing up. The published terms describe a strict commitment structure; the operational practice may include flexibility that isn't documented.

For the financial breakdown of what the 3-month commitment looks like in dollar terms, see our Novi cost analysis.

The Telehealth Consent Document and What It Acknowledges

Novi's published Medical Consent describes the limitations of telehealth in clear language. It acknowledges that, in rare cases, transmitted information may be insufficient for appropriate medical decision-making, that delays in evaluation could occur due to equipment failures, that security protocols could fail in very rare instances, and that lack of complete medical records may result in adverse drug interactions or judgment errors.

The consent also confirms that the platform does not replace emergency medical services. The Terms of Service repeat this in capital letters: “WE ARE NOT A REPLACEMENT FOR EMERGENCY MEDICAL SERVICES. IF YOU HAVE A MEDICAL EMERGENCY SEEK EMERGENCY MEDICAL CARE IMMEDIATELY IN-PERSON OR DIAL 911 OR YOUR LOCAL EMERGENCY NUMBER.”

This is standard for compliant telehealth platforms and reflects the actual scope of what telehealth can and cannot do. It also points to a real evaluation criterion: the right candidate for any compounded-GLP-1 telehealth program is a patient whose general health status is well-characterized through existing in-person medical care, who can independently recognize when symptoms exceed the telehealth scope, and who has appropriate in-person medical resources for situations that arise outside that scope.

Insurance, Medical Records, and HIPAA

Novi states that all prescriptions are cash-pay. Insurance reimbursement may be available for branded GLP-1 medications, but compounded options are positioned as the affordable cash-pay alternative. The platform is not enrolled as a participating provider in Medicare, Medicaid, or other federal or state healthcare programs.

Patient information is treated under HIPAA. Novi's Notice of Privacy Practices describes standard HIPAA-permissible uses for treatment, payment, and healthcare operations. Patients have the right to access their records, request amendments, request restrictions on disclosures, and file complaints with the platform's Compliance and Privacy Officer or with the U.S. Department of Health and Human Services Office for Civil Rights. The HIPAA contact line published in Novi's privacy practices is (844) 357-3601.

SMS messaging is opt-in. Per the published policy, mobile information is not shared with third parties for advertising purposes. Patients can opt out of SMS at any time by replying STOP.

The Honest-Broker Read on Novi's Safety and Cancellation Mechanics

Novi's published clinical screening process is consistent with standard telehealth-prescribing operations for the compounded GLP-1 category. The platform's terms are transparent about what telehealth can and cannot do. The contraindication screening relies on patient self-disclosure, which is true for the entire telehealth category.

The cancellation and refund mechanics are stricter than what some patients might assume from the marketing. The “cancel anytime” framing on the homepage is technically accurate — the cancellation request can be submitted anytime — but the contractual obligation to three months of payments isn't reversible based on tolerability or response to the medication. That structure isn't unusual in the compounded-GLP-1 telehealth category, but it should be understood explicitly before signing up.

For prospective Novi patients with a clean medical history and reasonable comfort with the GLP-1 side effect profile: the platform's clinical and policy structure is functional, transparent, and within category norms. For patients whose tolerance for side effects is uncertain, or who would want a one-month trial before committing financially, Novi's structure isn't a fit. We compare Novi's policies head-to-head with other compounded-GLP-1 platforms in our Novi vs SynergyRx vs TeleHealth Med comparison.

For the full editorial breakdown of what to evaluate before any compounded-GLP-1 commitment, see the core Novi review.

Bottom Line

The side effect profile of the medications Novi prescribes is well-documented and substantial — particularly during the first weeks of treatment and during dose escalation. The vast majority of side effects are gastrointestinal and self-limiting. A minority are more serious and require immediate clinical attention. The intake screening, like all telehealth screening, is only as thorough as the patient's disclosure of medical history.

The cancellation and refund terms are strict. The 3-month commitment is binding once treatment begins and a prescription is dispensed. The mechanism for managing intolerability is communication with the prescriber for dose adjustment, not discontinuation with refund. Patients who don't want that structure should evaluate platforms with different commitment terms.

Read the terms before signing. Ask the questions before paying. The platforms that answer cleanly are the ones running the program seriously.

Editorial note: This is a regulatory and clinical analysis for educational purposes. It is not medical advice. GLP-1 medications — both compounded and FDA-approved finished products — are prescription only and require evaluation by a licensed clinician. Compounded medications are not FDA-approved finished drugs.

The most important question for anyone considering a compounded GLP-1 telehealth program in May 2026 isn't about results. It's about supply chain.

Two days before this article was written — on April 30, 2026 — the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The proposal carries direct implications for how platforms like Novi can source the medications they prescribe. To understand what that means, the regulatory categories themselves need to be clear.

This article walks through the actual differences between compounded and brand-name GLP-1 medications, what 503A and 503B compounding mean, where Novi sits inside that framework, and how to ask the right diligence questions before committing to any compounded-GLP-1 telehealth program.

Brand-Name GLP-1 Medications: The FDA-Approved Finished Drugs

Four brand-name GLP-1 receptor agonist products dominate the conversation. Semaglutide is sold as Ozempic for type 2 diabetes management and as Wegovy for chronic weight management — both manufactured by Novo Nordisk. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management — both manufactured by Eli Lilly. Liraglutide is sold as Victoza (diabetes) and Saxenda (weight management) by Novo Nordisk.

These are FDA-approved finished drug products. The FDA reviewed and approved each specific formulation, dose strength, delivery device, and indication based on the manufacturer's clinical trial data. Manufacturing is conducted under FDA Current Good Manufacturing Practice (CGMP) regulations with full supply chain oversight.

The peer-reviewed clinical trial evidence for these products is substantial. The STEP trial program for semaglutide 2.4 mg reported average body weight reductions in the range of approximately 14.9% over 68 weeks in adults without type 2 diabetes. The SURMOUNT trials for tirzepatide 15 mg reported approximately 20.9% over 72 weeks. A 2026 systematic review across 22 randomized controlled trials with 41,757 individuals confirmed both molecules as effective for weight loss in patients with and without diabetes.

The trade-off is price. Cash-pay list prices for Wegovy and Zepbound have run above $1,000 per month at retail in the United States. Insurance coverage varies widely — many plans don't cover GLP-1 medications for weight management, only for diabetes. That gap is what created demand for the compounded category.

Compounded GLP-1 Medications: A Different Regulatory Framework

Compounding is the practice of preparing customized medications by combining or altering pharmaceutical ingredients to meet individual patient needs. It exists for legitimate reasons — patients with allergies to standard formulations, dose strengths not commercially available, alternative delivery routes, or pediatric customization.

The Federal Food, Drug, and Cosmetic Act recognizes two compounding categories.

Section 503A covers state-licensed pharmacies that compound patient-specific prescriptions. The model is typically: one prescription, one patient, one formulation. 503A operates primarily under state board of pharmacy regulation, not direct FDA premarket approval. The compounded product itself isn't FDA-approved as a finished drug — it's compounded based on a specific patient prescription.

Section 503B covers outsourcing facilities — larger-scale compounders that register with the FDA and operate under federal oversight. 503B facilities can produce compounded medications in batch quantity, including for office stock and provider distribution. They operate under requirements closer to (but not equivalent to) full pharmaceutical manufacturing.

The legal pathway for either category to compound copies of an FDA-approved drug is narrow. Generally, a 503A or 503B compounder may produce a copy only when (a) the FDA-approved product appears on the FDA's drug shortage list, or (b) for 503B specifically, the bulk active pharmaceutical ingredient is on the FDA's 503B bulks list, indicating clinical need.

For semaglutide and tirzepatide, both pathways were active during the 2022–2024 shortage period. Demand outstripped Novo Nordisk and Eli Lilly's manufacturing capacity. The FDA placed both molecules on the shortage list. Compounding pharmacies — both 503A and 503B — moved to fill the gap, often at $150 to $300 per month versus $1,000+ for the brand-name products. The scale was significant. By October 2025, IQVIA reporting indicated more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients (B vitamins, levocarnitine), which compounders cited as evidence of customization beyond simple copying — and which the FDA viewed with skepticism.

What Changed: The Wind-Down and the April 30, 2026 Proposal

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Both removals triggered phased enforcement deadlines for compounders to wind down operations. The Outsourcing Facilities Association filed federal lawsuits challenging both determinations. Courts denied preliminary injunctions in both cases. The wind-down deadlines held.

That left one remaining structural question for 503B compounding of these GLP-1 molecules: would the FDA add semaglutide, tirzepatide, or liraglutide to the 503B bulks list, which would have created an alternative legal pathway for ongoing 503B compounding regardless of shortage status?

The April 30, 2026 proposal answers that question. The FDA explicitly determined there is no clinical need to include any of the three molecules on the 503B bulks list. Per FDA Commissioner Marty Makary, MD, MPH, in the agency's announcement: “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need.”

The proposal is open for public comment through June 29, 2026, after which the FDA will consider submissions before issuing a final determination. If finalized, it formally closes the 503B pathway for bulk compounding of semaglutide, tirzepatide, and liraglutide — even in the event of a future shortage designation.

Patient safety data played a role. As of early 2025, the FDA had received over 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide. Many involved dosing errors from patients self-administering incorrect amounts from multidose vials, with some requiring hospitalization. Concerns about counterfeit products entering the market through online channels reinforced the agency's enforcement posture. We cover the side effect profile and Novi's specific patient safety mechanics in our side effects and cancellation policy review.

What This Means for 503A Compounding

The April 30 proposal targets 503B specifically. The 503A pathway — patient-specific compounding by state-licensed pharmacies — operates under a different statutory framework that doesn't depend on the 503B bulks list. As of early May 2026, 503A pharmacies continue to compound patient-specific prescriptions for semaglutide, tirzepatide, and liraglutide where state law permits and where the prescribing relationship is legitimate.

That said, the 503A pathway has its own constraints. 503A compounding is supposed to be patient-specific — produced for an individual patient on the basis of a specific prescription, not produced in bulk for office stock or undifferentiated patient populations. The “essentially a copy” doctrine — under which a compounder cannot legally produce a near-duplicate of an available FDA-approved drug — applies to both pathways. The line between legitimate 503A compounding and impermissible mass production is one the FDA, state pharmacy boards, and courts have been actively defining.

The practical implication: telehealth platforms historically supplied by 503B outsourcing facilities have already begun adapting. Some have shifted toward 503A pharmacy partnerships. Others have begun pivoting toward brand-name medication access at brand-name prices. Some have announced exits from the compounded GLP-1 category entirely.

Where Novi Sits in This Framework

Novi's published terms describe sourcing from “trusted, licensed U.S. pharmacies” and reference “pharmacy network providers” without naming specific partners or specifying 503A versus 503B status. The platform's marketing emphasizes that medications are “authentic and sourced from trusted, licensed U.S. pharmacies,” with quality and safety standards.

That's a transparency gap that prospective patients can close by asking. Specific questions that yield useful answers:

Are Novi's pharmacy partners 503A state-licensed pharmacies, 503B outsourcing facilities, or both? If 503B, are those facilities adapting their sourcing in light of the April 30, 2026 proposal? Does the platform plan to continue compounded sourcing if and when the proposal is finalized? Will pricing change if sourcing shifts? Are certificates of analysis (sterility, endotoxin, potency) available on request? Is the active ingredient semaglutide free base or sodium versus semaglutide acetate? (Acetate forms are not used in FDA-approved finished products and have been associated with quality concerns.)

These questions are answerable by support@joinnovi.com. The platforms that answer them clearly are differentiating themselves. The platforms that don't, in the current regulatory environment, are accepting transparency risk that prospective patients should weigh in their decision. Our broader analysis of how Novi compares against other platforms on disclosure and pharmacy network transparency is in the Novi vs SynergyRx vs TeleHealth Med comparison.

The Clinical Equivalence Question

A common claim in compounded-GLP-1 marketing — including some of Novi's marketing language — is that compounded versions contain “the same active ingredient as” the brand-name drug. This is technically defensible at the chemical level when the bulk API is genuine semaglutide free base or sodium produced to USP standards. It is not the same statement as saying the products are clinically equivalent.

FDA-approved finished products go through bioequivalence and clinical trial documentation that compounded versions don't. The finished formulation — the inactive ingredients, the buffer system, the delivery device, the manufacturing controls — affects pharmacokinetics, stability, and reproducibility. Two products with the same active ingredient at the same nominal dose may not deliver identical clinical outcomes if the finished formulation differs materially.

The published peer-reviewed efficacy data for semaglutide and tirzepatide — the 14.9% and 20.9% body-weight-reduction figures from the STEP and SURMOUNT trials — was generated using brand-name FDA-approved finished products. Whether and to what extent compounded versions deliver comparable outcomes hasn't been studied in equivalent trials. Treat outcome expectations on compounded versions as uncertain in a way they aren't with brand-name products.

For the broader pricing context that drives the choice between categories, see our Novi cost analysis.

What a Reasonable Decision Framework Looks Like

For a prospective patient evaluating compounded versus brand-name GLP-1 access through Novi or any similar platform, a reasonable evaluation framework includes:

The clinical fit. Whether GLP-1 therapy is medically appropriate, given BMI, comorbidities, contraindications, and goals. This is determined with a licensed clinician, not from a marketing page.

The regulatory fit. Whether the platform's pharmacy network operates under 503A or 503B, and whether the platform is positioned to adapt if the FDA proposal is finalized. Platforms that aren't transparent on this dimension carry more uncertainty than platforms that are.

The financial fit. Whether brand-name access through insurance is feasible (some plans cover Wegovy or Zepbound; many require prior authorization, BMI documentation, and step therapy). Whether brand-name cash-pay pricing is feasible. Whether the compounded-medication price point with a 3-month commitment is the right structure for the patient's situation.

The transparency fit. How the platform answers diligence questions. Whether certificates of analysis are available. Whether named pharmacy partners are disclosed.

The full picture of what to evaluate before signing up with Novi specifically is covered in our core Novi review.

Bottom Line

The compounded versus brand distinction matters more in May 2026 than it did in March 2026. The April 30 FDA proposal is a clear signal of regulatory direction. Compounded GLP-1 access through 503B facilities is being closed. 503A patient-specific compounding remains, but with constraints. Brand-name access remains the option with the strongest regulatory standing and the most clinical trial documentation.

For a prospective Novi patient: the platform's compounded-GLP-1 offering is real, available, and competitively priced. The 3-month commitment is the contractual structure. The pharmacy network and 503A/503B status is the question that determines how stable that offering is over the coming months. Ask before you sign.

The FDA's comment window closes June 29, 2026. By that date, the regulatory shape of this category becomes substantially clearer. Patients making decisions before then are making them under genuine regulatory uncertainty — and any honest review should say that out loud.

Editorial note: This pricing analysis reflects Novi's published terms and product pages as of May 2026. Pricing is subject to change. Compounded medications referenced are not FDA-approved finished drugs. Nothing in this article is medical or financial advice. Verify all current pricing on the official platform before any purchase.

The number you see on Novi's homepage — $174 — is real. It just isn't the full picture.

Most reviews of compounded GLP-1 telehealth platforms quote the headline price and stop. The published terms of service tell a more specific story about what you're committing to, what's included, and what changes if you cancel. This breakdown reads the terms alongside the marketing — so the cost decision is made on the actual numbers, not the front-page ones.

The Headline Pricing

Novi publishes two starting prices on the homepage. Compounded semaglutide is listed “from $174” and described as having the same active ingredient as Ozempic and Wegovy. Compounded tirzepatide is listed “from $283” and described as having the same active ingredient as Mounjaro and Zepbound. Both are labeled as monthly subscription pricing.

The “from” qualifier matters. These are starting prices for the lowest dose tiers — the prescriber's titration plan determines actual monthly cost. GLP-1 medications are typically initiated at low doses to minimize gastrointestinal side effects, then titrated upward over weeks to months. As dose increases, pricing on most compounded-GLP-1 telehealth platforms also increases. Novi's published materials don't specify the full per-tier price ladder. Confirm during the consultation.

The compounded versus brand-name distinction is the foundational pricing premise. Brand-name semaglutide (Wegovy) and brand-name tirzepatide (Zepbound) carry list prices well above $1,000 per month for cash-pay patients without insurance. The compounded category exists because of that gap — and because the FDA shortage of these molecules from 2022–2024 created a legal pathway for outsourcing facilities to compound copies. Both shortages have since been resolved, and the regulatory pathway is now actively being narrowed (more on that below). The $174 and $283 prices reflect that compounded category structure.

What's Included in the Monthly Fee

Per Novi's published program description, the monthly subscription fee covers: a 4-week supply of medication shipped each month, the supplies needed to administer it, a $20 independent physician consultation fee paid to an independent medical group, unlimited provider check-ins for dose adjustments and questions, and coaching at no additional cost.

The platform describes pricing as “all-in and transparent — no hidden fees, no separate membership, medication included.” Free 2-day shipping is referenced in the marketing. The published terms separately note that the user is responsible for “any applicable sales, use, duty, customs or other governmental taxes, levies or fees” and any shipping and handling charges shown at the time of purchase.

The reasonable read: the marketing's “all-in” framing applies to the routine monthly subscription cost, and any taxes or jurisdictional fees layer on top. Verify the order summary before confirming the first payment.

The 3-Month Commitment — In the Terms, Not the Marketing

This is the part that doesn't appear on the homepage and does appear in the terms of service. Quoting directly from Novi's published Terms of Service: “Subscription based Products and/or Services require a minimum 3-month commitment as We incur significant upfront cost to provide these Products and/or Services to you. By enrolling in Subscription Services, you agree to pay for a minimum of three (3) consecutive months of Service.”

The terms further specify: “the first month's fee as well as the monthly fee for the following two months (for a total of three (3) consecutive months) is charged at the time of purchase and is non-refundable unless our Providers deem it is not medically appropriate to prescribe you the ordered Products and/or Services.”

What this means in practical terms. When a new patient signs up and is approved for a prescription, all three months are charged upfront — or charged on the standard monthly cadence with the user contractually obligated to all three. The only refund pathway in the published terms is if a provider decides the treatment isn't medically appropriate before any prescription is dispensed. After that point, refunds aren't available under the terms.

For a $174/month semaglutide subscriber, the 3-month commitment translates to roughly $522 in obligated spend. For a $283/month tirzepatide subscriber, roughly $849. Those are the actual numbers a prospective Novi patient is committing to, regardless of how they respond to the medication.

The Cancellation Mechanics

Novi allows cancellation at any time, but the timing rules determine whether cancellation actually stops further charges. Per the published terms, cancellation must be submitted at least 15 days before the next monthly processing date — and only after the 3-month commitment has concluded — to stop subsequent renewals.

Cancellation can be submitted via email to support@joinnovi.com (the published support address) or through the patient dashboard on the website.

The other dimension worth knowing: once a prescription is dispensed or shipped, it cannot be returned or refunded under the published terms. That language applies whether or not the medication has actually been delivered to the patient — “dispensed” in pharmacy operations typically refers to the moment the pharmacy fills the prescription, before physical shipment.

The terms also explicitly address chargebacks: “False credit card disputes will be aggressively defended and customers who attempt to dispute charges to circumvent the 3-month commitment will be sent to collections and/or have further legal action pursued.” That's a clear operational stance. The 3-month commitment is contractually enforced.

The April 30, 2026 FDA Proposal — Pricing Implications

Two days before this analysis was written, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The public comment window runs through June 29, 2026. If finalized, the rule narrows the legal pathway for large-scale outsourcing facilities to produce compounded versions of these molecules from bulk active pharmaceutical ingredient.

The pricing implication is direct. The $174 and $283 price points exist because compounded sourcing is materially cheaper than brand-name finished pharmaceutical products. If 503B compounding of these molecules is foreclosed, platforms reliant on that pathway face a sourcing challenge — some may shift to 503A patient-specific compounding (a different legal framework, generally smaller volumes), some may pivot toward brand-name medications at brand-name prices, and some may exit the category. We discuss the regulatory mechanics in more depth in our Novi compounded vs brand analysis.

What this means for a prospective Novi patient evaluating the 3-month commitment today: pricing stability over the commitment window is not certain at the category level. The published terms allow Novi to adjust subscription pricing with notice. Whether and how the platform adapts its pricing to a finalized regulatory shift is something that will only be visible over the coming weeks. For broader context on the platform's clinical structure and what to ask before signing up, see the full Novi review.

What the Total 3-Month Cost Looks Like

The starting-price scenario, on the lowest published dose tier of compounded semaglutide, is roughly $522 over 3 months ($174 × 3) before any taxes. For compounded tirzepatide at the starting tier, roughly $849 ($283 × 3). Those numbers assume no dose escalation triggers a higher price tier inside the 3-month window — Novi's published materials don't disclose whether titration changes monthly cost, so confirm directly during the consultation.

Compared to brand-name pricing for cash-pay patients, that 3-month figure is substantially lower than three months of Wegovy (often $1,300+/month at retail) or Zepbound (similarly priced). It is meaningfully higher than a one-month trial of any of those platforms — because Novi's structure does not allow a one-month trial.

For consumers comparing Novi against other compounded-GLP-1 telehealth platforms, the headline price differentials are modest, but commitment structures, refund policies, and pharmacy network transparency vary. Our Novi vs SynergyRx vs TeleHealth Med comparison covers those dimensions head-to-head.

What's Not in the Pricing — But Affects Your Total Cost

Three categories of cost don't appear in Novi's headline pricing and may apply to specific situations.

Initial laboratory testing, if a provider recommends bloodwork as part of the eligibility screening. Novi's published process is primarily online intake, with lab work requested at provider discretion. Testing costs would typically be paid separately to a third-party lab.

Brand-name medication costs, if the provider determines a compounded option isn't appropriate and a branded medication is prescribed instead. Novi's primary offering is compounded; it isn't structured as a brand-name distributor at brand-name price points.

Side-effect-related costs. Most are minor and self-managed (anti-nausea over-the-counter products, hydration, dietary adjustments during titration). In rare cases involving serious adverse events, in-person clinical care may be necessary, and that care is outside Novi's telehealth scope. The platform's terms emphasize that telehealth is not a substitute for emergency medical care.

For a detailed look at side-effect management and the specific terms around how Novi handles cancellation when a patient is experiencing tolerability issues, see our Novi side effects and cancellation policy review.

The Honest-Broker Read on Novi's Pricing

Novi's pricing is competitive within the compounded-GLP-1 telehealth category. The headline numbers are real. The 3-month commitment is the structural cost detail that most reviews don't surface and that prospective patients should account for in their decision. Compared to the alternatives that operate without commitments, the trade-off is lower per-month pricing in exchange for less flexibility.

For broader context on how this category functions and what every prospective patient should evaluate before signing up — pricing, clinical structure, and the regulatory environment — see the TotalCareMedical.com weight management coverage at our weight management hub.

The pricing is fair for what's offered. The commitment structure is a real consideration. The regulatory environment is the wild card. Make the decision on all three, not just the front-page number.

Editorial note: This is an independent review by the TotalCareMedical.com editorial team. Novi is a telehealth platform operated by Novi International LLC. The compounded medications referenced — semaglutide and tirzepatide — are not FDA-approved finished drugs. Nothing in this review constitutes medical advice. GLP-1 medications are prescription only and must be evaluated by a licensed clinician for each individual.

Most reviews of compounded GLP-1 telehealth platforms read like they were written six months ago. That used to be fine. Two days ago, it stopped being fine.

On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory mechanism that has allowed large-scale outsourcing facilities to compound these GLP-1 medications during and after the 2022–2024 shortage period. Public comments are open through June 29, 2026. If finalized, the rule reshapes the compounded GLP-1 telehealth landscape that platforms like Novi operate inside.

This review reads Novi inside that new context. What the platform offers, what it costs, what happens when you cancel, what's clear in the terms of service and what isn't, and which questions the FDA proposal makes more important to ask before a 3-month commitment.

What Novi Is, and Who Operates It

Novi (joinnovi.com) is a direct-to-consumer telehealth weight management platform. It is operated by Novi International LLC, with a Wyoming registered address (30 N Gould St Ste R, Sheridan, WY 82801) and a Dallas, Texas operational address (4131 N Central Expy #900, Dallas, TX 75204). The platform's terms reference both “Novi International LLC” and “Novi Health LLC” — the latter appears in the binding arbitration section as the contracting party for disputes. Texas law governs the terms; arbitration runs through JAMS in Dallas County.

The model is straightforward. A user completes an online medical intake quiz, a US-licensed clinician reviews the submission and (when needed) conducts a virtual consultation, and — if treatment is determined to be medically appropriate — the user receives a prescription that ships from a licensed US pharmacy.

The marketed medications are compounded semaglutide (described by Novi as “same active ingredient as Ozempic® and Wegovy®,” from $174) and compounded tirzepatide (“same active ingredient as Mounjaro® and Zepbound®,” from $283). The platform offers free 2-day shipping and includes provider check-ins, dose adjustments, and coaching at no additional charge per its published program description. The monthly subscription fee includes a $20 independent physician consultation fee paid to an independent medical group.

Novi's published clinical team includes Daniel Funsch, MD (American Board of Emergency Medicine), Michael Wasef, MD (American Board of Internal Medicine), Takashi Nakamura, MD (American Board of Emergency Medicine), and several nurse practitioners — Kimberli Hastings, NP, Kristine Clements, NP, and Theresa Vergara, NP. The platform states services are limited to US residents 18 and older, and that prescribing is subject to state telehealth laws.

The April 30, 2026 FDA Proposal — and Why It Matters Here

The FDA's proposed rule, announced via a press release on April 30, 2026 and a Federal Register notice on May 1, would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. In plain terms: large-scale 503B outsourcing facilities would be barred from compounding these three drugs from bulk active pharmaceutical ingredient — closing a pathway that opened during the 2022 shortage and that powered much of the compounded-GLP-1 telehealth industry.

The mechanics matter. There are two compounding pathways. 503A pharmacies are state-licensed pharmacies that compound patient-specific prescriptions — one prescription, one patient, often customized. The FDA's April 30 proposal does not directly target 503A pharmacies; that pathway operates under a separate legal framework. 503B outsourcing facilities are larger compounders that produce in batch quantity and historically relied on the shortage list or the 503B bulks list as their legal basis. With both shortages now resolved (tirzepatide in December 2024, semaglutide in February 2025) and the 503B bulks listing now formally proposed for exclusion, the 503B pathway for these drugs is being closed.

Several major telehealth players have already announced shifts away from compounded GLP-1s. Patient safety reporting cited by the FDA includes more than 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide as of early 2025, with concerns including dosing errors and counterfeit supply.

For prospective Novi patients, the practical question is direct: which compounding pathway does Novi's pharmacy network operate under? Novi's published terms describe sourcing from “trusted, licensed U.S. pharmacies” but do not name the specific pharmacy partners or specify 503A versus 503B. That's a question worth asking customer support before signing the 3-month commitment, particularly given the regulatory direction.

The Pricing — and the 3-Month Commitment

Novi's headline pricing is $174/month for compounded semaglutide and $283/month for compounded tirzepatide. The “from” qualifier is in the marketing — actual pricing depends on dose tier and any pharmacy fees. Brand-name medications are not the platform's primary offering; the marketing explicitly positions the compounded options as the affordable alternative for cash-pay patients.

The detail that doesn't appear in the marketing copy and does appear in the published terms of service: subscription-based products on Novi require a 3-month minimum commitment. Per the terms, the first month's fee plus the next two months' fees (three months total) are charged at the time of purchase and are non-refundable, unless a provider determines treatment is not medically appropriate before any prescription is dispensed.

To cancel, the user must submit cancellation at least 15 days before the next monthly processing date — and only after the 3-month commitment period has concluded — to stop further charges. Once a prescription is dispensed or shipped, it can't be returned or refunded under any condition.

That structure is not unique to Novi. Several compounded-GLP-1 telehealth platforms use 3-month commitments. It's worth understanding before paying. A more granular pricing breakdown — including what's covered in the “all-in” monthly fee and what isn't — is in our companion Novi cost analysis.

What the Underlying Medications Do

The active ingredients Novi prescribes — semaglutide and tirzepatide — are GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide). Both classes work by mimicking incretin hormones the gut releases in response to food. The downstream effects include slowed gastric emptying, reduced appetite signaling, and improved glycemic control.

The peer-reviewed efficacy data for these molecules — at FDA-approved doses, in FDA-approved finished drug products — is substantial. Phase 3 trials of brand-name semaglutide 2.4 mg (the STEP program) have reported average body weight reductions in the range of approximately 14.9% over 68 weeks in adults without type 2 diabetes. Phase 3 trials of brand-name tirzepatide 15 mg (the SURMOUNT program) have reported reductions in the range of approximately 20.9% over 72 weeks in similar populations. A 2026 systematic review aggregating 22 randomized controlled trials with 41,757 individuals confirmed semaglutide 2.4 mg and tirzepatide at 5/10/15 mg doses as consistently effective for weight loss in patients with and without diabetes.

Three caveats that matter for any compounded-GLP-1 telehealth review. First, those trial outcomes were generated using FDA-approved finished products at specific doses with specific titration protocols — not using compounded versions. Second, individual results vary substantially. Third, the effect persists during treatment; discontinuation without sustained behavioral change is associated with weight regain in the published literature. Novi's marketing claim of “lose up to 24% of your body weight” is a marketing claim that exceeds the upper end of typical brand-name trial reporting and is not supported by published Novi-specific trial data. Treat it accordingly.

The Honest-Broker Read on the Clinical Process

Novi's published intake process — online questionnaire, clinician review, virtual visit when indicated, prescription when medically appropriate, ongoing provider access — is consistent with how most reputable compounded-GLP-1 telehealth platforms operate. The platform states it screens for eligibility based on standard medical criteria (BMI, comorbidities, contraindications), and that providers retain authority to deny treatment for misuse risk.

What's worth verifying with any compounded-GLP-1 telehealth platform — Novi included — before paying:

Whether the prescribing pathway is 503A or 503B, given the regulatory direction. The named pharmacy partners (compare against the FDA's registered outsourcing facility list at fda.gov). Whether certificates of analysis are available on request for sterility, endotoxin, and potency testing. Whether the medication is semaglutide free base or sodium versus semaglutide acetate (acetate forms have been associated with quality concerns and are not the form used in FDA-approved finished products). The full schedule of follow-ups and how dose titration is handled. The exact terms of the 3-month commitment relative to your state's telehealth and consumer protection laws.

Most of these are answerable by emailing support@joinnovi.com before committing. We discuss the compounded-versus-brand distinction in regulatory depth in our Novi compounded vs brand analysis.

What's Missing From Most Novi Reviews

Most third-party Novi reviews on the open web pre-date the April 30, 2026 FDA proposal entirely. They treat compounded GLP-1 access as a stable category. They quote the marketing testimonial figures (“Lost 52 lbs in 5 months”) as if those were verified outcomes. They don't address the 3-month commitment in the terms of service. And they don't ask about the pharmacy pathway.

This isn't unique to Novi. The same gap exists across reviews of SynergyRx, TeleHealth Med, and the broader compounded-GLP-1 category. The next 60–90 days will sort the platforms that adapt their sourcing from those that don't. A consumer evaluating any of these platforms today is making a 3-month commitment into a regulatory environment that's actively changing.

Side Effects, Safety Screening, and What to Expect

GLP-1 receptor agonists carry a documented side effect profile — primarily gastrointestinal. The most commonly reported in clinical trials and post-marketing data: nausea (14%–28% in published trials), vomiting (6%–12%), diarrhea (8%–20%), constipation, and decreased appetite. Most are most pronounced during dose titration and tend to attenuate as the body adjusts. Rarer but more serious risks include pancreatitis, gallbladder issues, and contraindications around personal or family history of medullary thyroid carcinoma, MEN2 syndrome, and certain pancreatic conditions.

Novi's intake process is designed to screen for these contraindications. The platform's documented telehealth consent acknowledges that virtual evaluation cannot substitute for in-person physical examination in all cases, and that some patients may need additional in-person clinical workup before treatment is appropriate. We cover the side effect profile and Novi's specific cancellation and refund mechanics in detail in our Novi side effects and cancellation policy review.

Who Novi Likely Fits — and Who It Doesn't

Novi may be a reasonable consideration for adults who meet standard prescribing criteria for GLP-1 weight management (BMI ≥30, or ≥27 with at least one weight-related comorbidity), who are seeking cash-pay access at compounded-medication price points, who can comfortably absorb a 3-month commitment regardless of how they respond to the medication, and who are willing to ask the regulatory pathway questions before paying.

Novi is not a fit for individuals with contraindications to GLP-1 therapy, those who require insurance coverage for brand-name medications, those who would need to discontinue at month one or two, those who require in-person clinical workup, or those who are uncomfortable with the compounded-medication category at all. The April 30, 2026 FDA proposal is an explicit signal that this category is contracting at the 503B level.

For a platform-by-platform comparison against the other two compounded-GLP-1 telehealth services we've reviewed, see our Novi vs SynergyRx vs TeleHealth Med comparison.

Bottom Line

Novi is a functioning compounded-GLP-1 telehealth platform with transparent published terms, a named clinical team, and competitive cash-pay pricing. The marketing is more aggressive than the documentation supports — the “up to 24% body weight” line and the prominent testimonial figures should be read as marketing, not as outcome data — but the underlying program structure is consistent with the category.

The real diligence question is not whether Novi works as advertised. It's whether the compounded-GLP-1 pathway Novi relies on continues to function as the FDA finalizes its April 30, 2026 proposal over the next several months. That answer depends on Novi's specific pharmacy network and whether it operates under 503A (still permitted), 503B (now under formal regulatory threat), or a combination. Any prospective patient considering a 3-month financial commitment is owed a straight answer to that question before paying.

Ask before you sign. The platforms that answer cleanly are the ones built to last past June 29, 2026.

Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. The eligibility criteria discussed in this article reflect Oak Longevity's published platform information and standard obesity medicine guidance. Final eligibility for any GLP-1 medication is determined by a licensed healthcare provider after review of the patient's complete health information. Nothing in this article constitutes medical advice or a guarantee of approval.

Eligibility is the variable that decides whether a compounded-GLP-1 telehealth platform is even an option for a given patient — and it is the variable most prospective patients learn about only during the intake, after they have already evaluated the platform on price. Oak Longevity's published eligibility framework is concise but not complete; the licensed provider doing the intake review applies a fuller clinical standard than the homepage exclusions imply. This guide covers what Oak publishes, what the standard obesity medicine eligibility framework includes, what disqualifies, and what to disclose during the intake.

Our editorial team analyzed Oak Longevity's published eligibility statements, the standard clinical eligibility framework used across compounded-GLP-1 telehealth platforms, and the contraindications that apply to GLP-1 receptor agonists regardless of platform. The clinical decision to prescribe — or to decline — belongs to the licensed provider reviewing the patient's complete health information, not to a marketing comparison or an eligibility article.

What Oak Longevity Publishes

Oak Longevity's published platform information specifies three categorical exclusions: the program is not appropriate for adults under 18, individuals who are currently pregnant or nursing, or individuals with BMI under 22 and no comorbidities. Beyond these stated exclusions, Oak's eligibility model defers to the licensed provider conducting the intake review. The provider — not the platform's marketing copy — determines clinical appropriateness based on the complete patient submission.

This structure is standard across the compounded-GLP-1 telehealth category. Mochi Health, Hims, SynergyRx, and TeleHealth Med all operate on the same model: a published categorical exclusion set, plus provider-discretion review for everything within the gray zones. The variation across platforms is in how rigorously the provider review is conducted — a question covered in our Oak vs Mochi vs Hims comparison — rather than in the underlying eligibility framework itself.

The Standard Obesity Medicine Eligibility Framework

The clinical standard applied across obesity medicine, including by licensed providers on compounded-GLP-1 telehealth platforms, has two thresholds. The first threshold is body mass index of 30 or higher, classified clinically as obesity. Patients meeting this threshold are eligible for pharmacologic weight management consideration regardless of comorbid conditions. The second threshold is BMI of 27 or higher with at least one weight-related comorbid condition. Patients meeting this lower BMI threshold qualify based on the combination of overweight status and the presence of a weight-related health risk that pharmacologic intervention may address.

This dual-threshold framework appears in the FDA-approved labeling for brand-name GLP-1 medications including Wegovy and Zepbound and is the operational standard for compounded versions of the same active ingredients. The peer-reviewed STEP and SURMOUNT trial programs that established the clinical evidence base for these medications enrolled patients meeting these criteria — not patients at lower BMIs without comorbidities.

Oak's published BMI-under-22-with-no-comorbidities exclusion is therefore a partial articulation of the broader clinical standard. Patients in the 22-to-26 BMI range without comorbidities are not categorically excluded by Oak's published rules, but a responsible licensed provider applying standard obesity medicine practice will frequently decline to prescribe in this range. The decline is not a platform failure; it is appropriate clinical conservatism. GLP-1 medications carry real risks, and prescribing them outside the evidence-supported eligibility framework increases risk without proportionate benefit.

What Counts as a Weight-Related Comorbidity

The BMI 27-plus eligibility threshold requires at least one weight-related comorbid condition. The conditions typically recognized in this framework include type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, polycystic ovary syndrome, and non-alcoholic fatty liver disease. Documentation strengthens the eligibility case substantially. A patient with a documented type 2 diabetes diagnosis supported by medical records — or a recent A1C lab value, or a current diabetes medication regimen — has a meaningfully stronger eligibility case at BMI 28 than a patient asserting “borderline blood sugar” without supporting documentation.

Patients evaluating Oak Longevity at BMI in the 27-29 range should plan to disclose specific comorbidities during the intake with as much specificity as possible. Diagnoses, A1C values, blood pressure readings, sleep study results, and lipid panel values all strengthen the case. Vague references to “feeling tired” or “concerned about diabetes” without supporting clinical documentation are unlikely to satisfy the licensed provider's review. The provider is not adversarial; the provider is applying clinical standards. Specificity helps.

For patients at BMI 30-plus, comorbidity documentation matters less for eligibility itself, but still matters for clinical management — the provider needs to know about co-existing conditions to prescribe appropriately, set realistic outcome expectations, and monitor for medication interactions.

Categorical Contraindications That Apply Everywhere

Beyond the BMI eligibility framework, GLP-1 receptor agonists carry contraindications that disqualify patients regardless of BMI or comorbidity status. These apply on Oak Longevity, on every competing compounded-GLP-1 telehealth platform, and on traditional in-person obesity medicine practices. Patients with these histories should not be approved for GLP-1 therapy, and the platform's intake should screen for them.

A personal or family history of medullary thyroid carcinoma is an absolute contraindication. The FDA-approved labeling for both semaglutide and tirzepatide carries a boxed warning related to thyroid C-cell tumors observed in animal studies. Patients with personal or family history of this rare thyroid cancer are not appropriate candidates for GLP-1 therapy.

Multiple Endocrine Neoplasia syndrome type 2 — a hereditary condition that elevates the risk of medullary thyroid carcinoma and other endocrine tumors — is the second absolute contraindication.

A history of pancreatitis is a relative contraindication that warrants particular clinical caution. GLP-1 medications have been associated with rare cases of acute pancreatitis. Patients with prior pancreatitis episodes should disclose this clearly during the intake; the provider may decline to prescribe or may prescribe with enhanced monitoring depending on the specifics.

Severe gastrointestinal disease, including gastroparesis or significant motility disorders, can be exacerbated by the slowed gastric emptying that GLP-1 medications produce. Patients with these conditions should disclose them.

Pregnancy and active attempts to conceive disqualify patients categorically. GLP-1 medications are not appropriate during pregnancy. Patients planning pregnancy should discuss the timeline with their provider; standard guidance recommends discontinuing GLP-1 therapy several months before attempting to conceive.

Active eating disorder history — particularly anorexia nervosa or bulimia — warrants careful clinical evaluation before starting GLP-1 therapy. The appetite-suppressing effect of these medications can complicate eating disorder recovery and is contraindicated during active illness.

The Intake Process — What Oak Will Ask

Oak's published intake follows the standard compounded-GLP-1 telehealth pattern: an online health questionnaire collecting medical history, current medications, weight history, lifestyle information, and screening for the contraindications above. The questionnaire is reviewed by a licensed provider who determines clinical appropriateness. If approved, a prescription is dispensed through a licensed compounding pharmacy partner with home delivery.

The questionnaire will ask about: current height and weight; goal weight; prior weight loss attempts; current medications including over-the-counter and supplements; allergies and adverse drug reactions; relevant medical history including thyroid conditions, pancreatic conditions, gastrointestinal conditions, cardiovascular conditions, mental health history including eating disorders; family history of medullary thyroid carcinoma or MEN2; pregnancy status or pregnancy plans; and lifestyle factors including alcohol use, tobacco use, and physical activity patterns.

Accurate disclosure is essential. Underreporting medical history to improve approval odds is operationally tempting and clinically dangerous. The provider's job is to prescribe safely; the patient's job is to give the provider the information needed to do that. Misrepresenting history to obtain a prescription that would not be approved with full disclosure is a path to serious adverse events that the platform's care team will not be able to address effectively because they will not know the actual clinical picture.

What Happens If the Provider Declines

If the licensed Oak provider determines that GLP-1 therapy is not clinically appropriate, the patient receives a decline rather than a prescription. The decline is not punitive; it reflects the provider's clinical judgment that the medication's risk-benefit profile does not favor treatment for this patient at this time. Common reasons for decline include: BMI in the gray zone without documented comorbidity; presence of contraindications including thyroid history; recent gastrointestinal complications; mental health history that warrants additional evaluation before GLP-1 initiation; or insufficient information in the intake to make a confident clinical decision.

Patients receiving a decline have several productive paths. The first is requesting clarification from the provider on what specifically would change the determination — sometimes additional documentation, lab work, or a coordinated discussion with the patient's primary care physician shifts the calculus. The second is seeking in-person obesity medicine evaluation, which provides a richer clinical picture than telehealth intake permits and may produce a different determination through a more thorough workup. The third is evaluating non-pharmacologic weight management strategies, including the evidence-based approaches covered in our broader Weight Management coverage.

What patients should not do is shop for a less rigorous platform. The eligibility framework exists for clinical safety reasons. A platform that approves patients other licensed providers decline is not offering more accessible care; it is operating with less clinical rigor, which is the opposite of what patients should want from a platform prescribing prescription medications.

Eligibility Verification Before Signing Up

Patients who want to evaluate likely eligibility before committing time to an intake can apply a simple framework. Calculate BMI: weight in kilograms divided by height in meters squared. BMI of 30 or higher is straightforward eligibility candidate territory. BMI of 27 to 29 with documented weight-related comorbidities is also straightforward eligibility candidate territory. BMI of 27 to 29 without documented comorbidities, or BMI under 27, is gray zone where licensed providers will frequently decline regardless of platform.

Beyond BMI, screen for the contraindications listed above. Personal or family history of medullary thyroid carcinoma or MEN2 is a categorical disqualifier. Active pregnancy or planning pregnancy in the near term disqualifies. Active eating disorder disqualifies. History of pancreatitis warrants disclosure and provider discussion before assuming eligibility.

For patients confident they meet the eligibility framework: the cost analysis covered in our Oak Longevity review, the platform comparison in our Oak vs Mochi vs Hims breakdown, the broader pricing analysis in Compounded Semaglutide Cost, and the side effect framework in Oak Longevity Side Effects are the next steps in evaluating whether Oak specifically — versus the alternatives — fits the patient's situation.

The Honest Read on Oak's Eligibility Framework

Oak Longevity's published eligibility exclusions are accurate but not complete. The licensed provider conducting intake review applies the broader clinical standard used across obesity medicine, which includes the BMI 30 or BMI 27-plus-comorbidity dual threshold and the categorical contraindications related to thyroid history, pregnancy, and pancreatic disease. Patients evaluating Oak should expect the provider review to be substantive, not a rubber stamp — and that substantive review is what makes the platform's prescriptions clinically defensible.

For patients clearly within the eligibility framework, Oak's no-membership-fee pricing structure and asynchronous intake produce a fast path from questionnaire to prescription. For patients in the gray zones, the provider's decision is the gating variable — and the platform's pricing structure does not change that decision. For patients with categorical contraindications, no compounded-GLP-1 telehealth platform is the right answer; in-person specialist evaluation is.

For broader category context and additional analysis, see our Telehealth Platform Reviews hub. The clinical decision to prescribe any GLP-1 medication, compounded or brand-name, belongs to the licensed provider — and the patient's role in that decision is honest, complete disclosure during intake.

Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Eligibility criteria reflect Oak Longevity's published platform information and standard obesity medicine clinical guidance; final eligibility is determined by the licensed provider during intake review. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs.